title: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
abstract: Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas. In general, their prognosis is poor, and specific therapy is not well defined. We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK). This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.
authors.affiliation: Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.
authors.forename: Rakhshandra
authors.initials: R
authors.lastname: Talpur
authors.forename: Narin
authors.initials: N
authors.lastname: Apisarnthanarax
authors.forename: Staci
authors.initials: S
authors.lastname: Ward
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004167:Diphtheria Toxin / Q000008:administration & dosage / Q000627:therapeutic use*; D004890:Erythema / Q000209:etiology; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009669:Nose Neoplasms / Q000188:drug therapy / Q000473:pathology; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016879:Salvage Therapy; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox